Humacyte (HUMA) Gross Profit (2025 - 2026)
Humacyte (HUMA) posted quarterly Gross Profit of -$1.5 million for Q1 2026, down 517.03% year-over-year from $370000.0 in Q1 2025, and up 82.09% quarter-over-quarter from -$8.6 million in Q4 2025.
Humacyte (HUMA) Gross Profit (2025 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Gross Profit for 2 consecutive years, with -$1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Profit fell 517.03% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at -$9.6 million (down 2688.38% YoY), while the FY2025 annual figure was -$7.7 million, changed N/A from the prior year.
- Gross Profit advanced to -$1.5 million in Q1 2026 per HUMA's latest filing, from -$8.6 million in the prior quarter.
- Across five years, Gross Profit topped out at $493000.0 in Q3 2025 and bottomed at -$8.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.00 Bn | 132.14 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.24 Bn | 60.06 Bn | 1.37 Bn |
| 4 | Moderna | 62.41 Bn | 57.27 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.18 Bn | 27.88 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.93 Bn | 10.54 Bn | 668.28 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - |
| 10 | Humacyte | 154.47 Mn | 154.47 Mn | -825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -825,000.00 |
| Jun 30, 2026 | -825,000.00 |
| Mar 31, 2026 | -1.54 Mn |
| Mar 31, 2026 | -1.54 Mn |
| Dec 31, 2025 | -8.62 Mn |
| Dec 31, 2025 | -8.62 Mn |
| Sep 30, 2025 | 493,000.00 |
| Sep 30, 2025 | 493,000.00 |
| Jun 30, 2025 | 88,000.00 |
| Jun 30, 2025 | 88,000.00 |
| Mar 31, 2025 | 370,000.00 |
| Mar 31, 2025 | 370,000.00 |